NDA 016324 · Legacy
Imuran
Azathioprine · Oral · Purine Antimetabolite
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1968
Mar 20, 1968
Approved uses
2
Original approval plus efficacy supplements
Registered trials
250
84 Phase 3, 33 recruiting
FAERS reports
88,646
76,823 serious, 8,939 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING - MALIGNANCY Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with IMURAN. See WARNINGS.
What it is approved for
From the label in effect Mar 19, 2026.
INDICATIONS AND USAGE: IMURAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: IMURAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of IMURAN on these variables has not been tested in controlled trials. Rheumatoid Arthritis: IMURAN is indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with IMURAN. The combined use of IMURAN with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of IMURAN with these agents cannot be recommended.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 13, 1981 Supplement 10 · Efficacy
- Mar 20, 1968 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- IMURAN · AZATHIOPRINE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- IMURAN · AZATHIOPRINE 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Azathioprine" as an intervention, any sponsor and status, largest first.
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
- HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's DiseasePivotal-lookingStatus unknown
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT05813860 · 976 participants (planned) · Start Apr 30, 2023 · Primary completion May 31, 2026
Drug: Azathioprine; Infliximab · For: Crohn Disease; Infliximab
- Cost-effectiveness of TPMT PharmacogeneticsPivotal-lookingCompleted
ZonMw: The Netherlands Organisation for Health Research and DevelopmentAcademic, hospital or other
NCT00521950 · 853 participants · Start Sep 2007 · Primary completion Dec 2011
Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP) · For: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis
Sites: Nijmegen, Netherlands; Oss, Netherlands; Veghel, Netherlands
- Determination of the Optimal Treatment Target in Ulcerative ColitisPivotal-lookingCompleted
Alimentiv Inc.Academic, hospital or other
NCT04259138 · 672 participants · Start Feb 18, 2020 · Primary completion Apr 13, 2026
Drug: Treatment Algorithm A; Treatment Algorithm B and 1 more · For: Colitis, Ulcerative
Sites: Ypsilanti, Michigan; New York, New York; Asheville, North Carolina · 58 sites in all
- A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00531817 · 619 participants · Start Oct 2007 · Primary completion Jun 2009
Drug: Tocilizumab; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Montgomery, Alabama; Lake Havasu City, Arizona · 157 sites in all
- Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular CarcinomaPivotal-lookingCompleted
University of RegensburgAcademic, hospital or other
NCT00355862 · 525 participants · Start Jan 2006 · Primary completion Apr 2009
Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free); Sirolimus · For: Hepatocellular Carcinoma
Sites: Regensburg, Germany
Centocor Ortho Biotech Services, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00094458 · 508 participants · Start Mar 2005 · Primary completion Apr 2008
Drug: infliximab infusion; AZA placebo caps; infliximab (IFX) placebo infusion; azathioprine (AZA) caps · For: Crohn Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 115 sites in all
- Immune Thrombocytopenia Management in AdultsPivotal-lookingStatus unknown
Nahda UniversityAcademic, hospital or other
NCT05861297 · 467 participants (planned) · Start May 5, 2020 · Primary completion Jan 18, 2024
Drug: Dexamethasone; Prednisolone and Azathioprine and 3 more · For: Immune Thrombocytopenia Purpura
Sites: Cairo, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use13,597
- drug ineffective13,160
- condition aggravated6,671
- arthralgia5,928
- diarrhoea5,574
- nausea5,296
- fatigue5,228
- headache4,493
- crohn^s disease4,362
- pain4,291
- pyrexia4,105
- pneumonia4,021
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 980 |
| 2005 | 798 |
| 2006 | 894 |
| 2007 | 967 |
| 2008 | 1,529 |
| 2009 | 1,603 |
| 2010 | 1,724 |
| 2011 | 2,441 |
| 2012 | 3,071 |
| 2013 | 3,073 |
| 2014 | 3,530 |
| 2015 | 3,922 |
| 2016 | 4,331 |
| 2017 | 4,273 |
| 2018 | 5,733 |
| 2019 | 6,600 |
| 2020 | 7,710 |
| 2021 | 6,295 |
| 2022 | 6,419 |
| 2023 | 5,922 |
| 2024 | 6,566 |
| 2025 | 6,379 |
| 2026 | 3,873 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imuran (Azathioprine)
2024 spending
$461K
Beneficiaries
101
453 claims
Per beneficiary
$4,565
$8.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $589,582 |
| 2021 | $529,864 |
| 2022 | $467,937 |
| 2023 | $434,393 |
| 2024 | $461,115 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM, Jones RB, Specks U, et al. · Ann Rheum Dis 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Raghu G, Anstrom KJ, King TE, et al. · N Engl J Med 2012 · Comparative Study, Multicenter Study
- Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L, Pagnoux C, Karras A, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies.
Beese SE, Price MJ, Tomlinson C, et al. · BMC Med 2025 · Systematic Review, Network Meta-Analysis
- Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, et al. · N Engl J Med 2010 · Comparative Study, Multicenter Study
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.